deltatrials
Completed PHASE2 NCT01962363

EPI-743 in Friedreich's Ataxia Point Mutations

A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations

Sponsor: Edison Pharmaceuticals Inc

Conditions Friedreich's Ataxia
Interventions EPI-743
Updated 6 times since 2017 Last updated: Jun 28, 2016 Started: Oct 31, 2013 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This PHASE2 trial investigates Friedreich's Ataxia and is currently completed. Edison Pharmaceuticals Inc leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Edison Pharmaceuticals Inc
  • Friedreich's Ataxia Research Alliance
  • University of South Florida
Data source: University of South Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tampa, United States